Skip to main content

Research Repository

Advanced Search

All Outputs (1)

What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? (2017)
Journal Article
Pellicori, P., Urbinati, A., Shah, P., MacNamara, A., Kazmi, S., Dierckx, R., …Clark, A. L. (2017). What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?. European journal of heart failure, 19(6), 768-778. https://doi.org/10.1002/ejhf.788

Aims The PARADIGM-HF trial showed that sacubitril–valsartan, an ARB–neprilysin inhibitor, is more effective than enalapril for some patients with heart failure (HF). It is uncertain what proportion of patients with HF would be eligible for sacubitril... Read More about What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?.